- Molecular NameBendroflumethiazide
- SynonymBendrofluazide; Bendroflumethazide; Bendroflumethiazidum [INN-Latin]; Bendroflumetiazida [INN-Spanish]; Bendrofumethiazide; Benzhydroflumethiazide; Benzydroflumethiazide; Benzylhydroflumethiazide; BHFT
- Weight421.42
- Drugbank_IDDB00436
- ACS_NO73-48-3
- Show 3D model
- LogP (experiment)1.19
- LogP (predicted, AB/LogP v2.0)1.59
- pka8.5
- LogD (pH=7, predicted)1.57
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.09
- LogSw (predicted, AB/LogsW2.0)0.03
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors4
- No.of HBond Acceptors7
- No.of Rotatable Bonds4
- TPSA135.12
- StatusFDA approved
- AdministrationN/A
- PharmacologyA thiazide diuretic used to treat hypertension.
- Absorption_value100.0
- Absorption (description)Readily and almost completely absorbed after oral administration.
- Caco_2N/A
- Bioavailability90.0
- Protein binding94.0
- Volume of distribution (VD)1.5 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmExtensive
- Half life9 h
- ExcretionUp to about 30% of a dose is excreted unchanged in the urine in 48 h; the remainder is excreted as unidentified metabolites.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe following have been reported: disturbances of electrolyte, acid-base balance, lipids, glucose and uric acid levels; thirst, polyuria, weakness, dizziness, muscle cramps and reversible impotence; nausea, vomiting, mild anorexia, gastric irritation, diarrhoea or constipation; rashes, skin reactions, purpura and blood dyscrasias including thrombocytopenia; hypocalciuria, precipitation of gout, pancreatitis, hepatic encephalopathy and postural hypotension.
- LD50 (rat)N/A
- LD50 (mouse)N/A